Sector News

EU clears plans by drugmakers GSK and Novartis to trade assets

January 29, 2015
Life sciences
(Reuters) – The European Commission on Wednesday approved a plan by Novartis (NOVN.VX) and GlaxoSmithKline (GSK.L) to trade more than $20 billion worth of assets, part of a reshaping of the drug industry at a time of healthcare spending cuts and more competition.
 
The companies agreed last April to the transaction that includes GSK buying Novartis’ vaccines business, Novartis purchasing GSK’s cancer drugs, and the two groups tying up in consumer healthcare.
 
The Swiss drugmaker will buy London-based GSK’s oncology products for $14.5 billion plus another $1.5 billion that depends on the results of a trial in melanoma.
 
The Commission said its approval was conditional on the divestment of two of Novartis’s cancer treatments – LGX818, a B-Raf inhibitor, and MEK162, an MEK inhibitor.
 
B-Raf inhibitors and MEK inhibitors are therapies that block cell proliferation, responsible for tumour growth and progression, and can be used to treat a number of different cancers.
 
The Commission said it had concerns that the transaction would have reduced competition and innovation for these products, but that the commitments address these concerns.
 
GSK is buying Novartis’ vaccines, excluding influenza, for $5.25 billion plus potential milestone payments of up to $1.8 billion and ongoing royalties. The companies also will form a joint venture in consumer healthcare.
 
“The decision is conditional upon the divestiture of assets in the vaccines and consumer health businesses,” the Commission, which acts as the EU’s anti-trust watchdog, said in a statement.
 
GSK has committed to divest one meningitis vaccine, grant a worldwide licence of another and offer further concessions in Germany and Italy, the Commission said.
 
The Commission had concerns the deal would hurt competition on developing meningitis and diphtheria tetanus vaccines, as well as products to stop smoking and to treat colds and pain.
 
GSK said that in Europe and Turkey, it had agreed to sell its NiQuitin products that help stop smoking and its Coldrex cold and flu products. In Sweden, it would sell its Panodil pain management, as well as its Nezeril/Nasin cold and flu products.
 
Novartis will sell its cold sore business in Europe.
 
GSK said it planned to complete the transactions with Novartis during the first six months of this year.
 
(Reporting by Philip Blenkinsop and Robin Emmott, editing by David Evans)

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).